Synthesis and evaluation of [ 18F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass

Nuclear Medicine and Biology

Volumn 39, Issue 2, 2012, Pages 167-176

  Wang, Yi ^a,b   Lim, Keunpoong ^a   Normandin, Marc ^a   Zhao, Xiaojian ^a   Cline, Gary W ^a   Ding, Yu Shin ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

18F Exendin (9 39); Diabetes; Glucagon like peptide 1 (GLP 1); HYNIC; Pancreatic cell mass; PET imaging

Indexed keywords

4 FLUOROBENZALDEHYDE; 6 HYDRAZINONICOTINYL; AMINE; BENZALDEHYDE DERIVATIVE; BIOLOGICAL MARKER; EXENDIN (9-39); EXENDIN (9-39) F 18; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR ANTAGONIST; INSULIN; LYSINE; NICOTINE DERIVATIVE; PANCRELIPASE; RECEPTOR BLOCKING AGENT; TRACER; UNCLASSIFIED DRUG; EXENDIN (9 39); FLUORINE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOBREEDING RAT; CELL MASS; CELLULAR PARAMETERS; CORRELATION ANALYSIS; DERIVATIZATION; DRUG CONJUGATION; DRUG PURIFICATION; DRUG PURITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ASSAY; HIGH RESOLUTION RESEARCH TOMOGRAPH; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LIVER; MEASUREMENT; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; POSITRON EMISSION TOMOGRAPHY; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; TOMOGRAPHY; ANIMAL; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; METHODOLOGY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, EXPERIMENTAL; FLUORINE RADIOISOTOPES; GLUCAGON-LIKE PEPTIDE 1; INSULIN; INSULIN-SECRETING CELLS; KIDNEY; LIVER; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84856359838     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.07.011     Document Type: Article

References (35)

1. Reubi J.C., Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003, 30:781-793.
2. Körner M., Stökli M., Waser B., Reubi J.C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007, 48:736-743.
3. Vilsbøll T., Agersø H., Krarup T., Holst J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003, 88:220-224.
4. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006, 60:1454-1470.
5. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402-7405.
6. Cvetković R.S., Plosker G.L. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007, 67:935-954.
7. Holst J.J. Pharmacology of GLP-1-based therapies. Br J Diabetes Vasc Dis 2008, 8:S10-S18.
8. Göke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 1993, 268:19650-19655.
9. 2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007, 13:3696-3705.
10. 2]Exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006, 47:2025-2033.
11. Christ E., Wild D., Forrer F., Brandle M., Sahli R., Clerici T., et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009, 94:4398-4405.
12. Wild D., Mäcke H., Christ E., Gloor B., Reubi J.C. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008, 359:766-768.
13. Wild D., Wicki A., Mansi R., Béhé M., Keil B., Bernhardt P., et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 2010, 51:1059-1067.
14. Fehmann H.C., Jiang J., Schweinfurth J., Wheeler M.B., Boyd A.E., Göke B. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides 1994, 15:453-456.
15. Mukai E., Toyoda K., Kimura H., Kawashima H., Fujimoto H., Ueda M., et al. GLP-1 receptor antagonist as a potential probe for pancreatic β-cell imaging. Biochem Biophys Res Commun 2009, 389:523-526.
16. Cline G.W., Carson R.E., Ding Y.S., Huang H., Weinzimmer D.P., Jakowski A., et al. Islet-selectivity of G-protein coupled receptor (GPCR) ligands evaluated for PET imaging. Diabetes 2008, 57(Suppl 1):A47.
17. Gotthardt M., Fischer M., Naeher I., Holz J.B., Jungclas H., Fritsch H.W., et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med 2002, 29:597-606.
18. Aspinwall S., McLaughlin W., Vizard D., Cline G. Molecular targeted fluorescent imaging of pancreatic beta-cell mass. 5th Annual Meeting of The Society for Molecular Imaging 2006, 132.
19. Kimura H., Ogawa Y., Kawashima H., Mukai E., Toyoda K., Fujimoto H., et al. Development of in vivo imaging agents targeting glucagon-like peptide-1 receptor (GLP-1R) in pancreatic islets. J Nucl Med 2009, 50(Suppl 2):326.
20. Jin C.H., Chae S.Y., Son S., Kim T.H., Um K.A., Youn Y.S., et al. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Control Release 2009, 133:172-177.
21. Son S., Chae S.Y., Kim C.W., Choi Y.G., Jung S.Y., Lee S., et al. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives. J Med Chem 2009, 52:6889-6896.
22. Chae S.Y., Jin C.H., Shin J.H., Son S., Kim T.H., Lee S., et al. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release 2010, 142:206-213.
23. Sweet I.R., Cook D.L., Lernmark A., Greenbaum C.J., Wallen A.R., Marcum E.S., et al. Systematic screening of potential β-cell imaging agents. Biochem Biophys Res Commun 2004;, 314:976-983.
24. 18F]GBR-13119. J Labelled Compd Radiopharm 1989, 27:823-838.
25. Carson R.E., Barker W.C., Liow J.S., Johnson C.A. Design of a motion compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. IEEE Nucl Sci Symp Conf Rec 2003, 3281-3285.
26. Dirksen A., Dawson P.E. Rapid oxime and hydrazone ligations with aromatic aldehydes for biomolecular labeling. Bioconjug Chem 2008, 19:2543-2548.
27. Dirksen A., Dirksen S., Hackeng T.M., Dawson P.E. Nucleophilic catalysis of hydrazone formation and transimination: implications for dynamic covalent chemistry. J Am Chem Soc 2006, 128:15602-15603.
28. 18F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol 2010, (in press) PMID 20824509.
29. Souza F., Simpson N., Raffo A., Saxana C., Maffei A., Hardy M., et al. Longitudinal noninvasive PET-based β cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 2006, 116:1506-1513.
30. 11C]DTBZ. Nucl Med Biol 2006, 33:855-864.
31. 99mTc-labeled bivalent MORF. Mol Pharmacol 2010, 7:1118-1124.
32. 99mTc-labeled radiopharmaceuticals. Bioconjug Chem 1999, 10:808-814.
33. He J., Liu G., Dou S., Gupta S., Rusckowski M., Hnatowich D. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjug Chem 2007, 18:983-988.
34. 18F using a hydrazone-formation method. Bioconjug Chem 2005, 16:1329-1333.
35. Runge S., Thøgersen H., Madsen K., Lau J., Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 2008, 283:11340-11347.